Digestery
Longevity supplements › Rapamycin and Aging › Studies

Opinion or narrative review

In mice, review of rapamycin studies: evidence strong for lifespan and age-related conditions

Selvarani and colleagues · GeroScience · 2021

Original title: Effect of rapamycin on aging and age-related diseases-past and future.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

Points to benefit

Review concludes mouse evidence for rapamycin is strong for lifespan and several age-related conditions, and that studies should move toward the clinic, for example for Alzheimer's disease.

The study at a glance

Type of study
Opinion or narrative review
Who or what was studied
Mostly mice
What was tested
Review of rapamycin's effects on lifespan, heart, brain, immune system and cell aging in mice
Who has a stake
No stake declared
No conflicts of interest declared.
Journal
GeroScience, 2021
Source
PubMed record 33037985. This page is based on the abstract only.

How much this study counts

  • –An opinion or narrative review: no new data, and no set method for choosing which studies to discuss.
  • ✓No competing interests declared.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

This paper is not on the ladder. It is a opinion or narrative review, and reviews and opinion pieces discuss studies that are already counted on the steps below.

↑ Stronger evidence

  1. Trials in people: aging and age-related decline

    3

    1 benefit, 1 mixed, 1 no difference

  2. Trials in people: other measures

    2

    2 no difference

  3. Trials in people: lab tests or safety

    2

    2 benefit

  4. Population studies

    1

    1 no direction

  5. Blood levels and genes

    0

    None among the papers we read.

  6. Animals

    2

    2 benefit

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does rapamycin slow aging in people?”

Not shown in people.

Confidence: very low. Based on 16 on-topic papers.

Read the full answer
  • Listed with the other papers, but not quoted in the page’s main findings.

Other opinion on this question

None among the papers we read.

See all 16 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The two reads agreed on every checked field. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.